| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Laboratory of Clinical Neurogenetics (Dr. Higgins, A. De Biase, and R.L. Adler), Wadsworth Center, New York State Department of Health, Albany, NY; Neurogenetics Clinic (Dr. Higgins) Westchester Medical Center, New Paltz, NY; the Department of Neurology (Dr. Golbe), UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ; Parkinson’s Disease Center and Movement Disorders Clinic (Dr. Jankovic), Department of Neurology, Baylor College of Medicine, Houston, TX; and Parkinson’s Disease Center and Movement Disorders Clinic (Dr. Factor), Albany Medical College, Albany, NY.
Address correspondence and reprint requests to Dr. Joseph J. Higgins, Director, Neurogenetics Clinic, Mid-Hudson Family Health Institute, 279 Main Street, New Paltz, NY 12561.
OBJECTIVE: To confirm the association of an extended 5'-tau haplotype on chromosome 17q with the disease phenotype in clinically ascertained individuals with sporadic progressive supranuclear palsy (PSP).
BACKGROUND: PSP is a neurodegenerative disease with parkinsonian signs accompanied by vertical supranuclear palsy and tau pathologic features. Previously, we documented the complete segregation of an extended 5'-tau haplotype consisting of four single nucleotide polymorphisms (SNP) with the disease phenotype in sporadic PSP. This study was conducted in an independent cohort to confirm these results and to improve the statistical power of the data. Design and
METHODS: Direct sequencing and restriction enzyme digests were used to analyze four SNP in tau Exons 1, 4A, and 8. These contiguous SNP were used to reconstruct an extended 5'-tau haplotype in 52 affected and 54 age-matched control individuals.
RESULTS: The four SNP formed two homozygous 5'-tau haplotypes (HapA and HapC) or a heterozygous genotype. Fifty-one (98%) patients with PSP had HapA; one (2%) with a later onset was heterozygous; and none had HapC. These PSP haplotype frequencies were different (p < 0.00001) from those of the age-matched control group, in which 18 (33%) people had HapA; 26 (48%) were heterozygous; and 10 (19%) had HapC. The extended 5'-tau haplotype, HapA, had a high sensitivity (98%) and a moderate specificity (67%) as a marker for PSP.
CONCLUSIONS: A 5'-tau susceptibility haplotype may be a sensitive marker for sporadic PSP and a genetic defect in, or closely linked to, tau may contribute to the cause of PSP.
This article has been cited by other articles:
|
|
 |
|
  P. D. Sundar, C.-E. Yu, W. Sieh, E. Steinbart, R. M. Garruto, K. Oyanagi, U.-K. Craig, T. D. Bird, E. M. Wijsman, D. R. Galasko, et al. Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia Hum. Mol. Genet., February 1, 2007; 16(3): 295 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Pittman, H.-C. Fung, and R. de Silva Untangling the tau gene association with neurodegenerative disorders Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R188 - R195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zampieri and R. P Di Fabio Progressive Supranuclear Palsy: Disease Profile and Rehabilitation Strategies Physical Therapy, June 1, 2006; 86(6): 870 - 880. [Full Text] [PDF]
|
|
|
|
|
|
R. Rademakers, S. Melquist, M. Cruts, J. Theuns, J. Del-Favero, P. Poorkaj, M. Baker, K. Sleegers, R. Crook, T. De Pooter, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy Hum. Mol. Genet., November 1, 2005; 14(21): 3281 - 3292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Morris, M. Baker, K. Yasojima, H. Houlden, M. N. Khan, N. W. Wood, J. Hardy, M. Grossman, J. Trojanowski, T. Revesz, et al. Analysis of tau haplotypes in Pick's disease Neurology, August 13, 2002; 59(3): 443 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Verpillat, A. Camuzat, D. Hannequin, C. Thomas-Anterion, M. Puel, S. Belliard, B. Dubois, M. Didic, B.-F. Michel, L. Lacomblez, et al. Association Between the Extended tau Haplotype and Frontotemporal Dementia Arch Neurol, June 1, 2002; 59(6): 935 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Wiggs The Human Genome Project and Eye Disease: Clinical Implications Arch Ophthalmol, November 1, 2001; 119(11): 1710 - 1711. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. K. Wszolek, Y. Tsuboi, R. J. Uitti, L. Reed, M. L. Hutton, D. W. Dickson, P. M. Stanford, G. M. Halliday, W. S. Brooks, J. B.J. Kwok, et al. Progressive supranuclear palsy as a disease phenotype caused by the S305S tau gene mutation Brain, August 1, 2001; 124(8): 1666 - 1670. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
